close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences, Inc. - Common Stock (NQ:ALPN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alpine Immune Sciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
From Alpine Immune Sciences Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
From Alpine Immune Sciences Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
From Alpine Immune Sciences Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Participation in May Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
From Alpine Immune Sciences Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event
From Alpine Immune Sciences Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Participation in January Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
From Alpine Immune Sciences, Inc. and Horizon Therapeutics plc
Via Business Wire
News headline image
Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces $91 Million Private Placement
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces Participation in September Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones Achieved Under AbbVie Collaboration
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Set to Join Russell 3000® Index
From Alpine Immune Sciences, Inc
Via Business Wire
News headline image
Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
News headline image
Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today